J Urol Oncol.  2023 Mar;21(1):32-44. 10.22465/juo.234600080004.

Epidemiology of Urologic Cancer in Korea: Nationwide Trends in the Last 2 Decades


This study assessed recent trends in the incidence of urologic cancer and patient survival in Korea.
Materials and Methods
The incidence of urologic cancer in Korea was calculated based on the Korea National Cancer Incidence Database and the South Korean Statistical Information Service Database. Data from 2000 to 2020 were used to determine the incidence, death, prevalence, and survival rates of urologic cancer.
Urologic cancer was diagnosed in 27,514 cases, accounting for 11.1% of the total cancer incidence. In 2020, there were 16,815 prostate cancer cases, 5,946 kidney cancer cases, and 4,753 bladder cancer cases. The age-standardized rate (ASR) for the incidence of prostate, kidney, and bladder cancer increased from 2000 to 2020. The overall ASR was 56 per 100,000 in 2020. In 2000, the ASRs for prostate, kidney, and bladder cancer were 2.9, 3.1, and 4.8 per 100,000, respectively, whereas they were 32.7, 11.6, and 9.3 per 100,000, respectively, in 2020. Urologic cancer has also seen a steady increase in the death rate, prevalence rate, and relative survival rate over the past 20 years. The 5-year relative survival rates for patients diagnosed with prostate cancer, kidney cancer, and bladder cancer during the 5-year period from 2015 to 2019 were 94.4%, 84.7%, and 76.5%, respectively. Among urologic cancers, prostate cancer had the highest survival rate, and bladder cancer had the lowest.
The survival rate for urologic cancer is increasing; however, the incidence and prevalence rates continue to rise.

Full Text Links
  • JUO
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr